Principles of Adjuvant Chemotherapy for Bone and Soft Tissue Tumors
The recent progress in the success of therapeutic effects on osteogenic sarcoma has been extraordinary and greatly enhanced by the contribution of adjuvant chemotherapy . The number of treatment courses in adjuvant chemotherapy that will be adequate to eradicate all tumor cells has become a matter of concern. The principles involved in this matter and a tentative conclusion are presented by an analysis of the therapeutic results of 48 patients with osteogenic sarcoma.
KeywordsAdjuvant Chemotherapy Osteogenic Sarcoma Soft Tissue Tumor Tumor Cell Kill Microscopic Disease
Unable to display preview. Download preview PDF.
- 1.Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221–1230Google Scholar
- 2.Skipper H, Schabel FM Jr, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 45: 5–28Google Scholar
- 4.Frei E, Jaffe N, Gero M, Skipper H, Watts H (1978) Adjuvant chemotherapy of osteogenic sarcoma: Progress and perspectives. J Natl Cancer Inst 60: 3–10Google Scholar
- 5.Cortes EP, Holland JF, Wang JJ, Glidewell 0 (1975) Adriamycin (NSC-123127) in 87 patients with osteosarcoma. Cancer Chemother Rep 6 (Part 3): 305–313Google Scholar
- 6.Ochs JJ, Freeman AI, Douglass HO Jr, Higby DS, Mindell ER, Sinks LF (1978) Cis-dichlorodiammine-platinum ( II) in advanced osteogenic sarcoma. Cancer Treat Rep 62: 239–245Google Scholar
- 8.Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos A (1976) Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163–2177Google Scholar
- 10.Shimoyama M, Niitani H, Kimura K (1975) Chemotherapeutic effect of cyclophosphamide and its related active compounds. 3. A design of optimal therapeutic schedules of these compounds (in Japanese). Jpn J Cancer Chemother 2: 889–901Google Scholar